The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in decreased expression of CDH1 protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in decreased expression of HMOX1 protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in decreased expression of NFE2L2 protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in decreased expression of NPHS2 protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in increased expression of ACTA2 protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in increased expression of CCL2 protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in increased expression of COL3A1 protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in increased expression of MMP7 protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in increased expression of PTGS2 protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in increased expression of SNAI1 protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in increased expression of VIM protein] ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in decreased expression of HMOX1 protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in decreased expression of NPHS1 protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in decreased expression of PODXL protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in decreased expression of SYNPO protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in decreased expression of WT1 protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in increased expression of CCL2 protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in increased expression of MMP7 protein]; ergosta-4,6,8(14),22-tetraen-3-one inhibits the reaction [AGT protein results in increased expression of PTGS2 protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CASP1 protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of CCL2 protein]
CYP51A1 gene inhibits the reaction [Fluconazole results in decreased chemical synthesis of Ergosterol]; CYP51A1 gene inhibits the reaction [Itraconazole results in decreased chemical synthesis of Ergosterol]; CYP51A1 gene inhibits the reaction [Ketoconazole results in decreased chemical synthesis of Ergosterol]; CYP51A1 gene inhibits the reaction [Voriconazole results in decreased chemical synthesis of Ergosterol]
[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of ICAM1 protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of IL1B protein; [Cholesterol co-treated with Ergosterol] results in increased expression of IL1B mRNA; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of IL1B protein]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of IL1B mRNA]
[Cholesterol co-treated with Ergosterol] results in increased expression of MAPK14 mRNA; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of MAPK14 mRNA]
[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of NLRP3 protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of OLR1 protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of PYCARD protein]
[Cholesterol co-treated with Ergosterol] results in increased expression of RELA mRNA; [Cholesterol co-treated with Ergosterol] results in increased expression of RELA protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of RELA mRNA]; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of RELA protein]
[Cholesterol co-treated with Ergosterol] results in decreased expression of SIRT1 mRNA; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in decreased expression of SIRT1 mRNA]
[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of VWF protein; resveratrol inhibits the reaction [[Cholesterol co-treated with Ergosterol] results in increased expression of and results in increased secretion of VWF protein]
withaferin A inhibits the reaction [[ABCB1 protein results in decreased susceptibility to Doxorubicin] promotes the reaction [Tetradecanoylphorbol Acetate results in increased expression of ABCB1 mRNA]]
withaferin A inhibits the reaction [IL1B protein promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]; withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]; withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of and results in increased activity of ADAM17 protein]; withaferin A inhibits the reaction [TNF protein promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]
withaferin A results in decreased expression of BCL2 protein withaferin A inhibits the reaction [Cholesterol, Dietary results in decreased expression of BCL2 protein]
withaferin A results in decreased expression of BCL2L11 protein withaferin A inhibits the reaction [Cholesterol, Dietary results in increased expression of BCL2L11 protein]
withaferin A binds to CDKN1A protein withaferin A results in increased expression of and affects the localization of CDKN1A protein withaferin A results in increased expression of CDKN1A mRNA
CLDN1 protein results in decreased susceptibility to withaferin A withaferin A results in decreased expression of CLDN1 mRNA; withaferin A results in decreased expression of CLDN1 protein
DDIT3 mRNA affects the susceptibility to withaferin A Acetylcysteine inhibits the reaction [withaferin A results in increased expression of DDIT3 protein]
[withanone co-treated with withaferin A] results in decreased expression of HNRNPK protein; withaferin A binds to and results in decreased activity of HNRNPK protein
withaferin A binds to HSPA9 protein [withaferin A inhibits the reaction [HSPA9 protein binds to TP53 protein]] which affects the localization of and results in increased activity of TP53 protein; [withanone co-treated with withaferin A] results in decreased expression of HSPA9 protein; withaferin A inhibits the reaction [HSPA9 protein binds to TP53 protein]
withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL6 mRNA]; withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate results in increased secretion of IL6 protein] withaferin A inhibits the reaction [Cholesterol, Dietary results in increased expression of IL6 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [withaferin A results in increased phosphorylation of MAPK1 protein]; [withanone co-treated with withaferin A] results in decreased expression of MAPK1 protein; Acetylcysteine inhibits the reaction [withaferin A results in increased phosphorylation of MAPK1 protein]; SOD2 protein inhibits the reaction [withaferin A results in increased phosphorylation of MAPK1 protein]; withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [withaferin A results in increased phosphorylation of MAPK3 protein]; [withanone co-treated with withaferin A] results in decreased expression of MAPK3 protein; Acetylcysteine inhibits the reaction [withaferin A results in increased phosphorylation of MAPK3 protein]; SOD2 protein inhibits the reaction [withaferin A results in increased phosphorylation of MAPK3 protein]; withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate results in increased phosphorylation of MAPK3 protein]
MCL1 mutant form promotes the reaction [withaferin A results in increased cleavage of PARP1 protein] withaferin A results in increased expression of MCL1 protein
Dithiothreitol inhibits the reaction [withaferin A results in increased cleavage of PARP1 protein]; MCL1 mutant form promotes the reaction [withaferin A results in increased cleavage of PARP1 protein]
withaferin A inhibits the reaction [IL1B protein promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]; withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]; withaferin A inhibits the reaction [TNF protein promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]]
withaferin A inhibits the reaction [[Lipopolysaccharides results in increased expression of PTGS2 protein] which results in increased chemical synthesis of Dinoprostone]; withaferin A inhibits the reaction [Lipopolysaccharides results in increased expression of PTGS2 mRNA]
SOD2 protein inhibits the reaction [withaferin A results in increased phosphorylation of MAPK1 protein]; SOD2 protein inhibits the reaction [withaferin A results in increased phosphorylation of MAPK3 protein]
withaferin A inhibits the reaction [Lipopolysaccharides results in increased phosphorylation of and results in increased localization of and results in increased activity of STAT1 protein]
withaferin A inhibits the reaction [TNF protein promotes the reaction [ADAM17 protein results in increased cleavage of PROCR protein]] withaferin A inhibits the reaction [Cholesterol, Dietary results in increased expression of TNF protein] withaferin A results in decreased activity of TNF protein
withaferin A results in increased expression of TP53 mRNA withaferin A binds to TP53 protein [withaferin A inhibits the reaction [HSPA9 protein binds to TP53 protein]] which affects the localization of and results in increased activity of TP53 protein; withaferin A inhibits the reaction [HSPA9 protein binds to TP53 protein]
[withanone co-treated with withaferin A] results in decreased secretion of VEGFA protein; withaferin A inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of VEGFA mRNA] withaferin A results in decreased expression of VEGFA protein
browse the term
